Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
P/E ratio for Oragenics, Inc. (OGEN)
P/E ratio as of 2023: -0.61
According to Oragenics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.61. At the end of 2022 the company had a P/E ratio of -0.89.
P/E ratio history for Oragenics, Inc. from 2003 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.61 |
| 2022 | -0.89 |
| 2021 | -3.20 |
| 2020 | -0.96 |
| 2019 | -1.42 |
| 2018 | -1.13 |
| 2017 | -1.72 |
| 2016 | -3.43 |
| 2015 | -4.69 |
| 2014 | -5.56 |
| 2013 | -5.03 |
| 2012 | -3.58 |
| 2011 | -0.75 |
| 2010 | -2.12 |
| 2009 | -3.53 |
| 2008 | -1.46 |
| 2007 | -4.45 |
| 2006 | -7.50 |
| 2005 | -1.99 |
| 2004 | -17.53 |
| 2003 | -29.57 |